Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mural Oncology plc - Ordinary Shares (NQ:MURA)

2.085 +0.005 (+0.24%)
Streaming Delayed Price Updated: 9:46 AM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mural Oncology plc - Ordinary Shares

< Previous 1 2 Next >
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
From Mural Oncology plc
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
From Mural Oncology plc
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, GTLS, MURA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, GES, MURA, TZUP on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
From Mural Oncology plc
Via GlobeNewswire
Mural Oncology Announces Plans to Explore Strategic Alternatives
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Participate in Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Present at Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
From Mural Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.